ClinicalTrials.gg
CompletedNCT03418324Updated Dec 30, 2020Results posted

Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy

A Phase 2 interventional study of TRC105 and Abiraterone in Prostate Cancer, sponsored by Cedars-Sinai Medical Center. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-30.

Sponsored by Cedars-Sinai Medical Center · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 13 studies in Prostatic Neoplasms by Cedars-Sinai Medical Center — 4 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · Cedars-Sinai Medical Center.

Enrollment
10th of 12
11 · median 47
Started
2018
with 1 other
Phase 2
5 of 13
2 open now
Registered
4th of 13
by date

Among the 13 studies in Prostatic Neoplasms by Cedars-Sinai Medical Center, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 2, and was the 4th registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

4 of the 13 studies in Prostatic Neoplasms by Cedars-Sinai Medical Center are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Prostatic Neoplasms by Cedars-Sinai Medical Center, or all of them as a file.
02

Study summary

This research study is being done to measure the clinical benefit of TRC105 in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or enzalutamide and showing signs of biochemical progression without radiographic progression. A patient who is progressing on AR-therapy will continue the same AR-therapy on study with the addition of TRC105. The two arms will accrue in parallel and independently.

Read the detailed description

This is a Phase II, open-label study of TRC105 (anti-endoglin antibody) in combination with abiraterone or enzalutamide in metastatic, castration-resistant prostate cancer patients who are taking either abiraterone or enzalutamide and showing signs of biochemical progression without radiographic progression. A patient who is progressing on AR-therapy will continue the same AR-therapy on study with the addition of TRC105. The two arms will accrue in parallel and independently.

There will be a 2-week washout of the active AR-targeted therapy prior to initiation of combination therapy. Tumor response should be assessed at a frequency of 8 weeks by CT/MRI chest, abdomen and pelvis as well as bone scan. Patients may continue on therapy until radiographic progression by RECIST 1.1 or PCWG3 criteria.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Metastatic Prostate Cancer
  • Castration Resistant Prostate Cancer
  • Metastatic Castration Resistant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. History of , castration-resistant prostate cancer with rising PSA on either abiraterone or enzalutamide

    • PSA rise will be defined as an increase in PSA of 0.2 ng/mL or higher on at least 2 separate occasions greater than 1 week apart while on either abiraterone or enzalutamide
    • If there is a drop in serum PSA after the first rise, and the patient has another PSA rise which is greater than the first, the patient will still be considered eligible.
  2. 0-2
  3. Resolution of adverse events results as described below.

    • Laboratory abnormalities must meet values specified below in criteria #4
    • If the patient's most recent is treatment with abiraterone or enzalutamide, then all adverse events must be resolved to Grade 2 or better
    • If the most recent line of therapy is any other treatment for mCRPC then all Adverse events must be resolved to grade 1 or better, with the exception of fatigue, alopecia and neuropathy (which must resolve to grade 2)
  4. Adequate organ function defined by:

    • and ALT \< 2.5 x
    • Total serum \< 1.5 x ULN
    • > 60,000
    • > 8.5 g/dL
    • Serum Cr \<1.5 x ULN or a > 30.
    • ≤ 1.2 unless the patient is receiving a direct Factor Xa inhibitor or a direct thrombin inhibitor
  5. Patients must be surgically sterile or must agree to use effective during the study and for 3 months following last dose of TRC105. The definition of effective contraception will be based on the judgment of the Principal Investigator or a designated associate. Abstinence from intercourse is an acceptable form of contraception.

Exclusion criteria

Exclusion Criteria:

  1. Non-PSA producing prostate cancers- such as small cell prostate cancers or those prostate cancers which exhibit radiographic progression without PSA rise
  2. Inability to tolerate standard doses of abiraterone (1000 mg daily) or enzalutamide (160 mg daily).
  3. Other prior requiring active anticancer therapy
  4. Prior exposure to TRC105 or any CD105 targeted antibody
  5. Any major surgical procedure within 2 weeks of starting therapy
  6. Uncontrolled chronic hypertension defined as sustained by systolic pressure (SBP) >150 mmHg or diastolic pressure (DBP) >90 despite optimal therapy.
  7. Active bleeding or pathologic conditions that carries a high bleeding risk
  8. Use of thrombolytics within 10 days prior to the first day of TRC105
  9. Known to Chinese hamster ovary products or other recombinant human, chimeric, or humanized antibodies
  10. A known diagnosis of Osler-Weber-Rendu syndrome
  11. Ascites or pericardial or pleural effusion requiring external drainage procedures
  12. History of untreated brain involvement with cancer, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or . Patients with radiated or resected lesions are permitted, provided the lesions are fully treated and inactive, patients are asymptomatic, and no have been administered for at least 28 days. Imaging for CNS disease will not be required for screening unless there is a history of a neurological finding such as new onset weakness or numbness that cannot be explained by other medical history.
  13. Acute cardiovascular event within the past 6 months. An acute cardiovascular event will be defined as a myocardial infraction, Class II or worse congestive heart failure, cerebrovascular accident, , arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or CABG. Deep venous thrombosis within 6 months, unless the patient is anti-coagulated without the use of warfarin for at least 2 weeks. In this situation, low molecular weight heparin is preferred.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Arm A: TRC105 + Abiraterone

    Patients progressing on Abiraterone will undergo a washout period and then continue treatment with TRC105 + Abiraterone

    Drug: TRC105 · Drug: Abiraterone

  • Experimental
    Arm E: TRC105 + Enzalutamide

    Patients progressing on Enzalutamide will undergo a washout period and then continue treatment with TRC105 + Enzalutamide

    Drug: TRC105 · Drug: Enzalutamide

Interventions

  • DrugCarotuximabStudies of CarotuximabCarotuximab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive TRC105 10mg weekly x 4, and then 15 mg/kg every 2 weeks

    Also known as: Carotuximab

  • Patients who are progressing on Abiraterone will undergo a washout period and then continue treatment with standard dosing of Abiraterone plus TRC105.

    Also known as: Zytiga

  • Patients who are progressing on Enzalutamide will undergo a washout period and then continue standard treatment with Enzalutamide plus TRC105.

    Also known as: Xtandi

06

What researchers measure

Primary outcomes

  1. Overall Clinical Benefit

    Number of participants with stabilization of disease for at least 2 months or disease improvement at any time from start of combination therapy by radiographic and/or biochemical criteria through treatment completion up to an estimated period of 24 months * radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria * Biochemical response will be defined by PCWG3 criteria * Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria

    Time frame: Through study completion, average 24 months

Secondary outcomes

  1. Adverse Events From TRC105 and Abiraterone or Enzalutamide

    Number of participants with grade 3/4 Adverse Events Related to investigational therapy as assessed Using CTCAE (v.4) up to 4 months from treatment initiation.

    Time frame: 4 months

  2. Progression Free Survival

    Time (in Months) from treatment initiation to radiographic and clinical progression over study duration (estimated 24 months) - radiographic criteria measured by RECIST 1.1 \[Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions plus an absolute increase of at least 5 mm, taking as reference the smallest sum recorded since the start of study\]

    Time frame: 24 months

  3. Clinical Benefit at Two Months

    Proportion of participants with stabilization of disease for two months or disease improvement at anytime from start of combination therapy to two months by radiographic and/or biochemical criteria * radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria * Biochemical response will be defined by PCWG3 criteria * Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria

    Time frame: 2 months

  4. Clinical Benefit at Four Months

    Proportion of participants with stabilization of disease for at least 4 months or disease improvement at anytime from start of combination therapy to four months by radiographic and/or biochemical criteria * radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria * Biochemical response will be defined by PCWG3 criteria * Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria

    Time frame: 4 months

  5. Clinical Benefit From PSA Serum Concentration (2 Months)

    Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.

    Time frame: 2 months

  6. Clinical Benefit From PSA Serum Concentration (4 Months)

    Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.

    Time frame: 4 months

07

Results

Posted Dec 30, 2020
Limitations and caveats
Early accrual closure due to manufacturer's limited drug supply.

Participant flow

Study opened to accrual February 5, 2018 and the first patient on study March 5, 2018. As of November 6, 2019, 12 patients have been consented, 11 were enrolled, and 11 were off-treatment and off-study. Study closed to accrual on May 1, 2019, as drug manufacturer has limited drug supply without plans to increase production.

Participant flow — Overall Study
MilestoneArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Started38
Completed26
Not completed12
Withdrew: Death01
Withdrew: Physician decision11

Outcome measures

PrimaryOverall Clinical Benefit

Number of participants with stabilization of disease for at least 2 months or disease improvement at any time from start of combination therapy by radiographic and/or biochemical criteria through treatment completion up to an estimated period of 24 months * radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria * Biochemical response will be defined by PCWG3 criteria * Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria

Time frame:
Through study completion, average 24 months
Reported as:
Count of participants · Participants
Overall Clinical Benefit
ParticipantsArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Overall Clinical Benefit14
Radiographic Improvement12
Biochemical Response11
Stabilization13
Statistical analysis
  • Arm A: TRC105 + Abiraterone · Binomial proportion: 50 · 95% CI 1.3 to 98.7Estimated values reflects the percentage of participants with overall clinical benefit.
  • Arm E: TRC105 + Enzalutamide · Binomial proportion: 66.7 · 95% CI 22.3 to 95.7Estimated values reflects the percentage of participants with overall clinical benefit
SecondaryAdverse Events From TRC105 and Abiraterone or Enzalutamide

Number of participants with grade 3/4 Adverse Events Related to investigational therapy as assessed Using CTCAE (v.4) up to 4 months from treatment initiation.

Time frame:
4 months
Reported as:
Count of participants · Participants
Adverse Events From TRC105 and Abiraterone or Enzalutamide
ParticipantsArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Grade 311
Grade 400
SecondaryProgression Free Survival

Time (in Months) from treatment initiation to radiographic and clinical progression over study duration (estimated 24 months) - radiographic criteria measured by RECIST 1.1 \[Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions plus an absolute increase of at least 5 mm, taking as reference the smallest sum recorded since the start of study\]

Time frame:
24 months
Reported as:
Median · months
Progression Free Survival
monthsArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Progression Free Survival1.64 (1.64 to NA)4.46 (1.71 to NA)
SecondaryClinical Benefit at Two Months

Proportion of participants with stabilization of disease for two months or disease improvement at anytime from start of combination therapy to two months by radiographic and/or biochemical criteria * radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria * Biochemical response will be defined by PCWG3 criteria * Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria

Time frame:
2 months
Reported as:
Count of participants · Participants
Clinical Benefit at Two Months
ParticipantsArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Clinical Benefit14
Radiographic Improvement11
Biochemical Response11
Stabilization13
Statistical analysis
  • Arm A: TRC105 + Abiraterone · Binomial proportion: 50 · 95% CI 1.3 to 98.7
  • Arm E: TRC105 + Enzalutamide · Binomial proportion: 66.7 · 95% CI 22.3 to 95.7
SecondaryClinical Benefit at Four Months

Proportion of participants with stabilization of disease for at least 4 months or disease improvement at anytime from start of combination therapy to four months by radiographic and/or biochemical criteria * radiographic improvement defined as a PR (At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum. There can be no appearance of new lesions) or CR (Disappearance of all target lesions, determined by two separate observations conducted not less than 4 weeks apart. There can be no appearance of new lesions) by RECIST 1.1 or improvement by PCWG3 criteria * Biochemical response will be defined by PCWG3 criteria * Stabilization will be defined as the absence of progression by BOTH radiographic and biochemical criteria

Time frame:
4 months
Reported as:
Count of participants · Participants
Clinical Benefit at Four Months
ParticipantsArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Clinical Benefit13
Radiographic Improvement12
Biochemical Response11
Stabilization12
Statistical analysis
  • Arm A: TRC105 + Abiraterone · Binomial proportion: 50 · 95% CI 1.3 to 98.7
  • Arm E: TRC105 + Enzalutamide · Binomial proportion: 50 · 95% CI 11.8 to 88.2
SecondaryClinical Benefit From PSA Serum Concentration (2 Months)

Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.

Time frame:
2 months
Reported as:
Count of participants · Participants
Clinical Benefit From PSA Serum Concentration (2 Months)
ParticipantsArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Clinical Benefit From PSA Serum Concentration (2 Months)14
SecondaryClinical Benefit From PSA Serum Concentration (4 Months)

Proportion of participants with stabilization of disease based on PSA serum concentration levels. Stabilization of disease refers to PSA values that do not meet criteria for progression where progression will be defined as a rise in serum PSA that is ≥ 25% and 2 ng/mL above nadir which is confirmed by a second value ≥ 3 weeks later.

Time frame:
4 months
Reported as:
Count of participants · Participants
Clinical Benefit From PSA Serum Concentration (4 Months)
ParticipantsArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Clinical Benefit From PSA Serum Concentration (4 Months)13

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: TRC105 + Abiraterone0/3 (0%)1/2 (50%)2/2 (100%)
Arm E: TRC105 + Enzalutamide1/8 (12.5%)0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Urinary retentionRenal and urinary disorders1/20/6
Cellulitis (peri-mandibular)Skin and subcutaneous tissue disorders1/20/6
HyponatremiaMetabolism and nutrition disorders1/20/6
Most frequent other events
Showing 10 of 55
Most frequent other events
EventArm A: TRC105 + AbirateroneArm E: TRC105 + Enzalutamide
Anemia Hemoglobin (Hgb)Blood and lymphatic system disorders2/22/6
EpistaxisRespiratory, thoracic and mediastinal disorders1/26/6
FallInjury, poisoning and procedural complications2/21/6
FatigueGeneral disorders2/20/6
Gingival bleedingGastrointestinal disorders2/25/6
Allergic reactionImmune system disorders1/20/6
Allergic rhinitisRespiratory, thoracic and mediastinal disorders1/20/6
AnorexiaMetabolism and nutrition disorders1/20/6
Back painMusculoskeletal and connective tissue disorders1/21/6
CoughRespiratory, thoracic and mediastinal disorders1/21/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm A: TRC105 + AbirateroneArm E: TRC105 + EnzalutamideTotal
<=18 years000
Between 18 and 65 years022
>=65 years246
Age, Continuous
Age, Continuous(years)Arm A: TRC105 + AbirateroneArm E: TRC105 + EnzalutamideTotal
Median76.5 (74 to 79)72 (57 to 73)72 (57 to 79)
Age, Continuous
Age, Continuous(years)Arm A: TRC105 + AbirateroneArm E: TRC105 + EnzalutamideTotal
Mean76.5 ± 3.5367.83 ± 6.9770 ± 7.25
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: TRC105 + AbirateroneArm E: TRC105 + EnzalutamideTotal
Female000
Male268
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: TRC105 + AbirateroneArm E: TRC105 + EnzalutamideTotal
Hispanic or Latino000
Not Hispanic or Latino268
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: TRC105 + AbirateroneArm E: TRC105 + EnzalutamideTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White167
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Arm A: TRC105 + AbirateroneArm E: TRC105 + EnzalutamideTotal
United States268
08

Study locations

1 site
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Nov 2019, 20 months.

Results were first posted in Dec 2020, 1 year 1 month after primary completion.

Of 612 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's 20 months is below that.

Counting every sponsor, half of 726 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2018
First posted
Feb 1, 2018
StartActual
Mar 5, 2018
Primary completionActual
Nov 6, 2019
CompletionActual
Nov 6, 2019
Results first posted
Dec 30, 2020
Last update
Dec 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03418324
Responsible party
Edwin Posadas, MD (Medical Director, Urologic Oncology Program, Cedars-Sinai Medical Center) — Principal investigator
First posted
Feb 1, 2018
Start date
Mar 5, 2018
Primary completion
Nov 6, 2019
Completion
Nov 6, 2019
Results posted
Dec 30, 2020
Last update
Dec 30, 2020

Study contacts

Edwin Posadas, MD FACP
principal investigator · Cedars-Sinai Medical Center Samuel Oschin Comprehensive Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion